Previous Close | 0.0035 |
Open | 0.0023 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's Range | 0.0022 - 0.0037 |
52 Week Range | 0.0010 - 0.0200 |
Volume | |
Avg. Volume | 367,800 |
Market Cap | 733,129 |
Beta (5Y Monthly) | -0.40 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -0.0700 |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Subscribe to Yahoo Finance Plus to view Fair Value for ENDV
US Army Medical Research and Development Command Vendor Day Los Angeles, CA, March 04, 2024 (GLOBE NEWSWIRE) -- SofPulse Inc. -- a subsidiary of Endonovo (OTC PINK: ENDV) and a proposed spin-off company -- announced today the participation of its SofPulse® Pulsed Electro-Magnetic Field (PEMF) FDA-cleared medical device in the United States Army Medical Research and Development Command (USAMRDC) May 2024 Vendor Day. The USAMRDC is the Army's medical materiel developer, responsible for medical res
Los Angeles, CA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV), a commercial-stage developer of wearable products for pain relief, general wellness, and wound curatives marketed under the SofPulse® brand name, announced the signing of a definitive agreement for the sale of the SofPulse® business and medical Intellectual Property (IP) to SofPulse, Inc.. ENDV is expected to receive the greater of $50 million or a price to be determined by a qualified third party's ass
Los Angeles, CA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) US-based medical device company, today announced the full regulatory approval of its flagship product, SofPulse® by the Taiwan Food and Drug Administration (TFDA), the regulatory division of the Ministry of Health and Welfare (MOHW). The approval is a significant accomplishment in introducing innovative Pulsed Electro Magnetic Field (PEMF) technology into the Taiwanese surgical market through Endonovo's